Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Bo Kyeung | - |
dc.contributor.author | Yoon, Jung | - |
dc.contributor.author | Bae, Joon-Yong | - |
dc.contributor.author | Kim, Jeonghun | - |
dc.contributor.author | Park, Man-Seong | - |
dc.contributor.author | Lee, Suk Yong | - |
dc.contributor.author | Lim, Chae Seung | - |
dc.date.accessioned | 2022-02-13T17:41:12Z | - |
dc.date.available | 2022-02-13T17:41:12Z | - |
dc.date.created | 2022-01-19 | - |
dc.date.issued | 2021-12 | - |
dc.identifier.issn | 2075-4418 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/135648 | - |
dc.description.abstract | Rapid and accurate measurement of SARS-CoV-2 neutralizing antibodies (nAbs) can aid in understanding the development of immunity against COVID-19. This study evaluated the diagnostic performance of a rapid SARS-CoV-2 nAb detection test called the BZ COVID-19 nAb test BZ-nAb (BZ-nAb; BioZentech). Using the 90% plaque-reduction neutralization test (PRNT-90) as a reference, 104 serum specimens collected from COVID-19-positive and -negative patients were grouped into 40 PRNT-90-positive and 64 PRNT-90-negative specimens. The performance of the BZ-nAb was compared with that of the cPass surrogate virus neutralization test (cPass sVNT; Genscript). The BZ-nAb showed a sensitivity ranging from 92.5%-95.0% and specificity ranging from 96.9%-100%, whereas cPass sVNT showed a sensitivity of 100% (95% confidence interval (CI) 90.5%-100%) and specificity of 98.4% (95% CI, 91.6%-100%). The dilution factor obtained with PRNT-90 showed a stronger correlation with the percent inhibition of cPass sVNT (r = 0.8660, p < 0.001) compared with the test and control line ratio (T/C ratio) of the BZ-nAb (r = -0.7089, p < 0.001). An almost perfect agreement was seen between the BZ-nAb and cPass sVNT results, with a strong negative correlation between the BZ-nAb T/C ratio and cPass sVNT percent inhibition (r = -0.8022, p < 0.001). In conclusion, the diagnostic performance of the BZ-nAb was comparable to that of the cPass sVNT, although the BZ-nAb had a slightly lower sensitivity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.subject | VALIDATION | - |
dc.subject | ASSAY | - |
dc.title | Performance Evaluation of the BZ COVID-19 Neutralizing Antibody Test for the Culture-Free and Rapid Detection of SARS-CoV-2 Neutralizing Antibodies | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Man-Seong | - |
dc.identifier.doi | 10.3390/diagnostics11122193 | - |
dc.identifier.scopusid | 2-s2.0-85120179044 | - |
dc.identifier.wosid | 000736587700001 | - |
dc.identifier.bibliographicCitation | DIAGNOSTICS, v.11, no.12 | - |
dc.relation.isPartOf | DIAGNOSTICS | - |
dc.citation.title | DIAGNOSTICS | - |
dc.citation.volume | 11 | - |
dc.citation.number | 12 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | ASSAY | - |
dc.subject.keywordPlus | VALIDATION | - |
dc.subject.keywordAuthor | COVID-19 | - |
dc.subject.keywordAuthor | ELISA | - |
dc.subject.keywordAuthor | RDT | - |
dc.subject.keywordAuthor | SARS-CoV-2 | - |
dc.subject.keywordAuthor | neutralizing antibodies | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.